HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NCT07169552 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-12-17
Summary
Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)
Conditions
Interventions
- DRUG
-
HC010
HC010 Q3W intravenous infusion
Sponsors & Collaborators
-
HC Biopharma Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-09
- Primary Completion
- 2026-12-30
- Completion
- 2027-09-30
Countries
- China
Study Locations
More Related Trials
-
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
NCT07171606 ·Status: RECRUITING ·Phase: PHASE2
-
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
NCT06883552 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
NCT02793856 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HS248 in Patients With Advanced Solid Tumors
NCT05759234 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
NCT06101082 ·Status: RECRUITING ·Phase: PHASE1
-
Effect of Chemotherapy on PD-L1 in NSCLC
NCT03701607 ·Status: UNKNOWN
-
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
NCT05205421 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
NCT03525782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
NCT03432598 ·Status: COMPLETED ·Phase: PHASE2
-
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
NCT06586697 ·Status: RECRUITING ·Phase: PHASE2
-
Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment
NCT03053219 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
NCT04199559 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC
NCT03700333 ·Status: UNKNOWN ·Phase: PHASE3
-
Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy
NCT03046316 ·Status: RECRUITING ·Phase: NA
-
A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
NCT04976647 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
NCT07251166 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06091943 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
NCT06477523 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
NCT07244016 ·Status: RECRUITING
-
SB17170 Phase 1 Clinical Trial in Solid Tumors
NCT05522868 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
NCT04911907 ·Status: COMPLETED ·Phase: PHASE2
-
Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
NCT04663438 ·Status: UNKNOWN